Jun Gao

Prof. Jun Gao


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Biomaterials
Verified
Journal Article
Closed access
TTTian Tian
Tian Tian
HZHui-Xin Zhang
Hui-Xin Zhang
CHChun-Peng He
Chun-Peng He
SFSong Fan
Song Fan
YZYan-Liang Zhu
Yan-Liang Zhu
JGJun Gao
Jun Gao

19 February 2019 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
HZHuixin Zhang
Huixin Zhang
JWJin Wu
Jin Wu
JWJiahuan Wu
Jiahuan Wu
QFQi Fan
Qi Fan
JZJingchao Zhou
Jingchao Zhou
JGJun Gao
Jun Gao
Accumulating evidence shows that microRNA-210 (miR-210) holds great promise to improve angiogenesis for brain tissue repair after cerebral ischemia. However, safe and efficient delivery of miR-210 via intravenous administration is still a challenge. In the past decade, exosomes have emerged as a novel endogenous delivery system. Here, c(RGDyK) peptide is conjugated to exosomes, and they are loaded with cholesterol-modified miR-210 (RGD-exo:miR-210). In a transient middle cerebral artery occlusion (MCAO) mouse model, the RGD-exo:miR-210 targets the lesion region of the ischemic brain after intravenous administration, resulting in an increase in miR-210 at the site. Furthermore, RGD-exo:miR-210 are administered once every other day for 14 days, and the expressions of integrin β3, vascular endothelial growth factor (VEGF) and CD34 are significantly upregulated. The animal survival rate is also enhanced. These results suggest a strategy for the targeted delivery of miR-210 to ischemic brain and provide an angiogenic agent for the treatment of ischemic stroke.

1 January 2021 in Theranostics
Verified
Journal Article
Open access
TTTian Tian
Tian Tian
LCLei Cao
Lei Cao
CHChuan He
Chuan He
QYQing Ye
Qing Ye
RLRuyu Liang
Ruyu Liang
JGJun Gao
Jun Gao
Ischemic stroke remains a major cause of death, and anti-inflammatory strategies hold great promise for preventing major brain injury during reperfusion. In the past decade, stem cell-derived extracellular vesicles (EVs) have emerged as novel therapeutic effectors in immune modulation. However, the intravenous delivery of EVs into the ischemic brain remains a challenge due to poor targeting of unmodified EVs, and the costs of large-scale production of stem cell-derived EVs hinder their clinical application.

31 January 2022 in ACS Nano
Verified
Journal Article
Closed access
TTTian Tian
Tian Tian
RLRuyu Liang
Ruyu Liang
GEGulsah Erel-Akbaba
Gulsah Erel-Akbaba
LSLorenzo Saad
Lorenzo Saad
POPierre J. Obeid
Pierre J. Obeid
BTBakhos A. Tannous
Bakhos A. Tannous

23 December 2016 in Scientific Reports
Verified
Journal Article
Open access
LZLing-Yan Zhao
Ling-Yan Zhao
WXWan-Lin Xu
Wan-Lin Xu
ZXZeng-Qi Xu
Zeng-Qi Xu
CQCui Qi
Cui Qi
YLYang Li
Yang Li
JYJin-hai Ye
Jin-hai Ye
TRPM2, one member of the transient receptor potential (TRP) protein super-family, is a Ca2+-permeable channel that is activated by oxidative stress and confers susceptibility to cell death. In the human tongue specimens of carcinoma and the tongue carcinoma SCC cell lines, we observed the enhanced expression of TRPM2. By means of the whole-cell electrophysiological recording, the ADPR-induced currents mediated by TRPM2 were recorded in cultured SCC9 cells. Moreover, after H2O2 treatment for 24 hours, the apoptotic number of SCC9 cells was significantly increased. However, the selectively knocked-down TRPM2 with the small interfering RNA technique inhibited the survival and migration of the SCC9 cancer cells, which was independent of the p53-p21 pathway, since the expression of p21 was enhanced after TRPM2 knockdown. Furthermore, the sub-cellular localization of TRPM2 was remarkably different between cancerous and non-cancerous cells. A significant amount of the TRPM2 proteins were located in the nuclei in cancer cells. All these data suggest that TRPM2 is essential for the survival and migration of SCC cancer cells and may be a potential target for the selective treatment of tongue cancer.